Algernon Pharmaceuticals Inc. (CSE: AGN)
Canada
· Delayed Price · Currency is CAD 0.0800
+0.0050 (6.67%)
Jan 17, 2025, 4:00 PM EST
Algernon Pharmaceuticals Revenue
Revenue
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
n/a
Market Cap
1.70M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Green Thumb Industries | 1.51B |
| Curaleaf Holdings | 1.83B |
| WELL Health Technologies | 957.69M |
| dentalcorp Holdings | 1.51B |
| Trulieve Cannabis | 1.58B |
| Sienna Senior Living | 867.55M |
| Cronos Group | 150.26M |
| Extendicare | 1.42B |
Algernon Pharmaceuticals News
- 5 weeks ago - Algernon CEO Discusses Ifenprodil Sale to Seyltx and DMT as a Treatment for Stroke and TBI - BNN Bloomberg
- 6 weeks ago - How Algernon Pharmaceuticals is Unlocking Sub-Psychedelic DMT for Stroke and TBI Treatment - BNN Bloomberg
- 2 months ago - Algernon Announces Warrant Extension - GlobeNewsWire
- 5 months ago - Algernon Pharmaceuticals Announces Closing of Private Placement - GlobeNewsWire
- 5 months ago - Algernon Pharmaceuticals Announces Increase to Private Placement - GlobeNewsWire
- 5 months ago - Algernon Pharmaceuticals Announces Private Placement - GlobeNewsWire
- 8 months ago - Algernon Pharmaceuticals Engages ICP Securities Inc. for Automated Market Making Services - GlobeNewsWire
- 9 months ago - Algernon NeuroScience and the Centre for Human Drug Research to Present DMT Phase 1 Stroke Clinical Data at the Interdisciplinary Conference on Psychedelic Research June 6 – 8th, 2024 - GlobeNewsWire